Days after Australia issued an advisory against counterfeit rabies vaccine in India, a public sector manufacturer of the vaccine ‘Abhayrab’ clarified that the concern revolves around a specific batch identified in January 2025, and did not merit a blanket warning against it.
The vaccine manufacturer, the Indian Immunologicals Limited (IIL), said the advisory in its present form has the potential to create anxiety and mistrust among the public and healthcare practitioners. It asked the Australian government to consider reviewing its advisory.
Around a week ago, the Australian Technical Advisory Group on Immunisation (ATAGI) said Australian travellers who have been administered the anti-rabies vaccine Abhayrab in India after November 1, 2023, should consider the vaccination invalid and initiate a new course of vaccination.
The IIL has written to ATAGI, strongly refuting the “over-cautionary and misplaced reference” to a batch of vaccine manufactured in March 2024, and said it had …​Days after Australia issued an advisory against counterfeit rabies vaccine in India, a public sector manufacturer of the vaccine ‘Abhayrab’ clarified that the concern revolves around a specific batch identified in January 2025, and did not merit a blanket warning against it.
The vaccine manufacturer, the Indian Immunologicals Limited (IIL), said the advisory in its present form has the potential to create anxiety and mistrust among the public and healthcare practitioners. It asked the Australian government to consider reviewing its advisory.
Around a week ago, the Australian Technical Advisory Group on Immunisation (ATAGI) said Australian travellers who have been administered the anti-rabies vaccine Abhayrab in India after November 1, 2023, should consider the vaccination invalid and initiate a new course of vaccination.
The IIL has written to ATAGI, strongly refuting the “over-cautionary and misplaced reference” to a batch of vaccine manufactured in March 2024, and said it had … ​Latest News [ SOBAN NEWS: International and National ]
